FDA makes end of Zepbound, Mounjaro shortage official

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded counterparts. 

By Kristin Jensen • Oct. 3, 2024

Lilly plans $4.5B ‘foundry’ for advanced drug manufacturing

With its latest investment, Lilly is looking toward medicines of the future and new methods to produce them.

By Kristin Jensen • Oct. 2, 2024

Sanofi readies to meet US demand for RSV antibody

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in full supply this RSV season.

By Delilah Alvarado • Sept. 16, 2024

As Biosecure bill advances, drugmakers prepare for prospect of China pivot

While companies’ exposure to the Biosecure Act varies, drugmakers are bracing for the knock-on effects that its passage could create in the market for contract services.

By Amy Baxter • Sept. 16, 2024

Novartis builds out radiopharma production with expansion, new factory

A planned facility in California will boost Novartis’ West Coast supply chain as new uses for the company’s radioligand therapies grow.

By Kristin Jensen • Sept. 4, 2024

Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues

Company executives had warned investors that a delay was likely due to issues at a facility run by a third-party manufacturer.

By Kristin Jensen • Aug. 21, 2024

Novo plans new plant as it races to meet drug demand

The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.

By Ned Pagliarulo • Aug. 19, 2024

Evotec, citing research spending slowdown, cuts jobs and exits gene therapy

New CEO Christian Wojczewski announced layoffs that will affect about 7% of the company’s workforce.

By Kristin Jensen • Aug. 14, 2024

Zepbound, Mounjaro back in supply as Lilly resolves shortage

All doses of the in-demand GLP-1 medicines are now available in the U.S., Lilly said ahead of reporting second quarter earnings later this week.

By Ned Pagliarulo • Aug. 5, 2024

Novo to spend $4B on US plant, adding to obesity drug production push

The planned facility in North Carolina is Novo’s latest multibillion-dollar investment in the manufacturing of weight loss drugs, demand for which continues to outstrip supply.

By Jonathan Gardner • June 25, 2024

Balancing phase-appropriate needs with commercial readiness in viral vector manufacturing

The MilliporeSigma viral vector team has unlocked unique insights and workflows that can guide innovators through steps they might not even realize they needed to take.

June 10, 2024

Lilly to pour $5B more into expanding Zepbound, Mounjaro production

The planned spending on new facilities in Lebanon, Indiana, brings its total commitment to the site to $9 billion, the largest single manufactuing investment in company history.

By Ned Pagliarulo • May 24, 2024

As drug shortages reach record highs, regulators weigh next steps

With many chemotherapy and ADHD drugs stuck in stubbornly short supply, several agencies are looking for new solutions.

By Kelly Bilodeau • May 6, 2024

Lilly counts on manufacturing scale-up to unstick obesity drug supply

Increasing the production capacity for Zepbound and Mounjaro is “the most ambitious expansion plan in our company’s history,” said CEO David Ricks.

By Jonathan Gardner • April 30, 2024

Sustainability in pharmaceutical manufacturing: a CDMO’s contribution

Consideration of sustainability early in process development, throughout the entire development cycle, and across the entire supply chain must also become common practice.

By Mark McLaws, Ph.D. – Vice President CMC & Development, Asymchem • April 29, 2024

Lilly to buy injectable drug plant in manufacturing ramp-up

The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.

By Delilah Alvarado • April 22, 2024

Bristol Myers taps startup to boost cell therapy production

A partnership with Cellares, worth up to $380 million, is meant to help Bristol Myers speed and scale manufacture of CAR-T treatments for cancer.

By Ned Pagliarulo • April 22, 2024

Keeping cleanrooms clean: Choosing the right laboratory equipment is key

 Because live cell and tissue products are sensitive to contamination from microorganisms, viral particles or other  impurities, research and manufacturing involving these materials needs to be conducted in a cleanroom environment.

April 15, 2024

Novartis pauses enrollment in some Kisqali trials to fix manufacturing

The company said the pause is necessary to meet regulatory limits on nitrosamine, but added it will not affect commercial supply nor regulatory review of the drug in early breast cancer.

By Jonathan Gardner • April 10, 2024

BIO changes stance, backs bill to limit China’s role in US biotech

Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with WuXi-AppTec, a major contract manufacturer to the biopharmaceutical industry.

By Jonathan Gardner • March 14, 2024

Advanced technologies in unlocking the future of drug manufacturing

Innovative technologies, such as flow chemistry and biocatalysis, are achieving not only sustainability goals but also unprecedented levels of quality and efficiency.

By Jon Brice, PhD • March 11, 2024

BioNTech partners with Autolus to boost cell therapy manufacturing

The German biotech will invest $200 million in Autolus — funds that, along with a $50 million fee, give it licensing options and access to supply infrastructure.

By Kristin Jensen • Feb. 8, 2024

Fujifilm to invest $200M in cell therapy production

The funds are meant to boost Fujifilm’s capacity to manufacture cell therapies, a market it expects to grow substantially in the coming years.

By Delilah Alvarado • Dec. 6, 2023

Novo to expand French plant in GLP-1 production push

The planned $2.3 billion investment follows an earlier $6 billion commitment to expand manufacturing for drugs like its in-demand medicine Wegovy.

By Delilah Alvarado • Nov. 27, 2023

Data infrastructure excellence changing the shape of biopharma manufacturing

Biopharma companies capture data across a variety of different fronts and, so this data must be managed effectively in order to unlock business efficiencies and drive improvements.

Nov. 20, 2023